Madison Square Garden Sports Corp. heads into its May 8 earnings release with short sellers quietly adding pressure even as several analysts raised targets in recent weeks.
The most notable development in positioning is the steady accumulation of short interest. SI has climbed 24% over the past month to 5% of the free float — a meaningful move for a stock this thinly traded on the short side. The build has been consistent: shares short rose every session last week, adding another 4.5% over five days. Yet the lending market shows no signs of stress. Borrow costs are running at just 0.53% annualised, barely changed over the past month, and availability remains loose — borrow demand relative to supply is well below historical peaks. There is no squeeze pressure building here; the short accumulation looks deliberate rather than distressed. Options positioning reinforces that calm: the put/call ratio is at 0.61, actually below its 20-day average of 0.68, suggesting options traders are not hedging aggressively into the print.
The analyst picture is genuinely mixed, and that divergence is worth naming. Citigroup's Jason Bazinet downgraded the stock to Neutral on April 23 — raising his target to $355 at the same time, a combination that captures the tension between franchise value and near-term upside. Guggenheim maintained its Buy and lifted its target to $401 on April 21. Seaport Global upgraded to Buy with a $430 target on April 10. Against those constructive moves, the consensus remains a Hold, with four of seven analysts sitting on the fence and the mean target at $378 — implying roughly 11% upside from the current $340. Bulls point to the irreplaceable nature of the Knicks and Rangers franchises, the pricing power embedded in arena revenue, and long-run asset appreciation well above book value. Bears counter with the NBA luxury tax burden, the dependence on team performance for revenue visibility, and the $19 million drag from the restructured MSG Networks media deal.
T. Rowe Price added 331,730 shares in the most recent quarter — the largest incremental buy among institutional holders — taking its stake to 5.6% of shares outstanding. BlackRock also added modestly. The Dolan Family Trust, controlling 19.2% of the company, trimmed by 37,247 shares. The most recent insider transaction on record was a February sale by Director Charles Dolan totalling roughly $1.8 million across three trades, though that was made at prices near $325, below the current level.
The May 8 print will test whether franchise asset appreciation and arena economics can sustain a valuation that carries an EV/EBITDA multiple above 500x on trailing earnings — a level that demands the growth story remain intact even as one bellwether firm has just stepped to the sidelines.
See the live data behind this article on ORTEX.
Open MSGS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
